)
Lexicon Pharmaceuticals (LXRX) investor relations material
Lexicon Pharmaceuticals Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline and catalysts
Strategic focus on serious cardiometabolic disease, with late- and early-stage programs advancing across the pipeline.
Sotagliflozin’s phase III SONATA trial in HCM is fully enrolled, with a Q1 2027 readout; type 1 diabetes NDA resubmission is planned for Q1 2027, with potential approval in 2027.
AAK1 diabetic peripheral neuropathy program is phase III-ready; work continues across additional AAK1 indications, while Novo Nordisk-partnered LX9851 is in obesity and other indications.
SONATA and HCM opportunity
SONATA enrolled 542 patients: 440 non-obstructive and 102 obstructive; about 40 patients were taking a cardiac myosin inhibitor at entry.
Primary endpoint is KCCQ change at week 24 across obstructive and non-obstructive HCM; the study was powered for an approximately five-point placebo-adjusted difference.
Management expects a similar KCCQ effect across both subgroups, citing sotagliflozin’s proposed diastolic effects; it highlighted substantial unmet need in non-obstructive HCM.
Rationale includes dual SGLT1/2 activity, myocardial SGLT1 expression, effects on thromboembolic mechanisms, and cardiorenal benefits; management characterized the medicine as once-daily, oral, safe and tolerable.
Q1 topline is expected to include the primary endpoint across the combined population and safety details; most secondary endpoints are planned for a later medical meeting.
Type 1 diabetes and safety
FDA discussions aligned on at least 200 patient-years of exposure and a DKA rate below the inTandem program’s ~3.5 cases per 100 patient-years.
STENO1 data through end-August met both criteria, with 200 patient-years of exposure and ~1 DKA case per 100 patient-years, similar to untreated controls and below inTandem; enrollment continues.
Management said the additional safety criteria were met and the resubmission file is being prepared; sotagliflozin could be the first and only adjunct to insulin for type 1 diabetes.
- SONATA-HCM results and a ZYNQUISTA resubmission are targeted for Q1 2027.LXRX
Q3 2026 - Late-stage pipeline advances and key trial readouts set up major milestones by early 2027.LXRX
H.C. Wainwright 28th Annual Global Investment Conference - Phase III HCM data for sotagliflozin expected Q1, with strong pipeline and regulatory momentum.LXRX
12th Annual Cantor Fitzgerald Global Healthcare Conference - SONATA-HCM phase III data expected Q1 2027, with T1D resubmission and pipeline advances underway.LXRX
Citigroup’s Biopharma Back to School Summit 2026 - Shares registered for resale by warrant holders; no proceeds to company; focus on heart failure drugs.LXRX
Registration filing - Q2 2026 net loss was $31.8M; SONATA-HCM Phase 3 enrollment completed, NDA resubmission Q4 2026.LXRX
Q2 2026 - Major clinical and partnership milestones achieved, with pivotal data and regulatory catalysts ahead.LXRX
Evercore ISI 8th Annual HealthCONx Conference - Multiple late-stage programs approach pivotal milestones, with regulatory and clinical catalysts ahead.LXRX
Jefferies London Healthcare Conference 2024 - LX9211 and pilavapadin advance as non-opioid therapies with imminent phase IIb data in DPNP.LXRX
R&D Day 2025
)
)
)
)
)
)
)
)